Thoratec Reports Third Quarter Results

                    Thoratec Reports Third Quarter Results

- Quarterly Revenue of $117.8 million, an Increase of 15% Year-Over-Year

- HeartMate II® Worldwide Unit Growth of 27% for the Third Quarter and 23% for
the First Nine Months of 2012

- GAAP Net Income per Diluted Share of $0.41, an Increase of 32%
Year-Over-Year and Non-GAAP Net Income per Diluted Share of $0.49, an Increase
of 19% Year-Over-Year

- Full-Year Revenue Guidance Increased to a Range of $477 million to $483
million

PR Newswire

PLEASANTON, Calif., Nov. 1, 2012

PLEASANTON, Calif., Nov. 1, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ:
THOR), a world leader in device-based mechanical circulatory support therapies
to save, support and restore failing hearts, today reported its financial
results for the third quarter of 2012.

"Thoratec delivered excellent results during the third quarter, demonstrating
continued momentum in the global VAD market as well as HeartMate II's strong
competitive position," said Gary F. Burbach, President and Chief Executive
Officer. "HeartMate II unit volume expanded by 27% during the third quarter
and 23% for the first nine months of the year, driven by the U.S. Destination
Therapy indication and healthy underlying trends in international markets," he
added.

For the quarter ended September 29, 2012, Thoratec reported revenues of $117.8
million, a 15 percent increase over revenues of $102.6 million in the third
quarter of 2011. Net income on a GAAP basis was $24.3 million, or $0.41 per
diluted share, compared with GAAP net income of $19.0 million, or $0.31 per
diluted share, in the same period a year ago. Non-GAAP net income, which is
described later in this press release, was $29.2 million, or $0.49 per diluted
share, compared with non-GAAP net income of $25.1 million, or $0.41 per
diluted share, in the same period a year ago.

For the first nine months of fiscal 2012, revenues were $363.2 million, an
increase of 16 percent over revenues of $313.3 million in the same period a
year ago. Net income on a GAAP basis was $70.6 million, or $1.18 per diluted
share, compared with GAAP net income of $57.2 million, or $0.95 per diluted
share, in the same period a year ago. Non-GAAP net income was $86.6 million,
or $1.45 per diluted share, compared with non-GAAP net income of $74.3
million, or $1.18 per diluted share, in the same period a year ago.

"I am highly encouraged by the outlook for the investments we are making in
both market development and product development," Burbach commented. "Our
market development efforts continue to drive strong performance in our
HeartMate II product line, and with respect to our product development
portfolio, we remain on track to initiate pivotal clinical trials for both
HeartMate III and HeartMate PHP™ during 2013."

Third Quarter and First Nine Months of 2012 Financial Results

For the third quarter of 2012, Thoratec reported revenues of $117.8 million,
an increase of 15 percent compared to the same quarter last year. Currency
fluctuations decreased revenues by two percent. The HeartMate product line
contributed $105.9 million, an increase of 21 percent, while the Centrimag
product line contributed $7.5 million, an increase of four percent, including
incremental revenues of $0.9 million related to the acquisition of Levitronix
Medical. The PVAD/IVAD product line contributed $3.8 million, a decrease of
47%.

For the first nine months of 2012, Thoratec reported revenues of $363.2
million, an increase of 16 percent, compared to the same period last year.
Currency fluctuations decreased revenues by one percent. The HeartMate product
line contributed $323.8 million to revenues, an increase of 19 percent, while
the CentriMag product line contributed $24.2 million, an increase of 43
percent, including revenues of $6.1 million related to the acquisition of
Levitronix Medical. The PVAD/IVAD product line contributed $13.4 million, a
decrease of 39 percent.

For the third quarter of 2012, GAAP gross margin was 69.3 percent compared to
67.9 percent in the same quarter last year. The increase in GAAP gross margin
was due primarily to inventory fair market adjustments recorded in the third
quarter of 2011. Non-GAAP gross margin, described later in this press release,
was 71.4 percent compared to 71.6 percent in the same quarter last year. The
decrease in non-GAAP gross margin was due to unfavorable currency
fluctuations, partially offset by volume-based efficiencies.

For the third quarter of 2012, GAAP operating expenses were $48.9 million
compared to $41.9 million in the same quarter last year. Non-GAAP operating
expenses, described later in this press release, were $43.2 million compared
to $36.3 million in the same quarter last year. The increase in non-GAAP
operating expenses was due primarily to product and market development
initiatives.

Cash and investments were $307.9 million as of September 29, 2012, compared to
$279.8 million as of June 30, 2012 and $209.5 million as of December 31, 2011.

GUIDANCE

The following statements are based on current expectations. These statements
are forward-looking and actual results may differ materially. For a more
detailed discussion of forward-looking statements, please see the additional
information below. The company updated guidance for the full year.

The company expects revenues for fiscal 2012 will be in the range of $477 to
$483 million. GAAP net income per diluted share is expected to be in the
range of $1.40 to $1.44, and non-GAAP net income per diluted share is expected
to be in the range of $1.79 to $1.83.

CONFERENCE CALL/WEBCAST INFORMATION

Thoratec will hold a conference call to discuss its financial results and
operating activities for all interested parties at 1:30 p.m., Pacific Daylight
Time (4:30 p.m., Eastern Daylight Time), today. The teleconference can be
accessed by calling (719) 325-4815, passcode 9452100. Please dial in 10-15
minutes prior to the beginning of the call. The webcast will be available
through Thursday, November 8, via http://www.thoratec.com or by telephone at
(719) 457-0820, passcode 9452100.

GAAP TO NON-GAAP RECONCILIATION

Thoratec management evaluates and makes operating decisions using various
measures. These measures are generally based on revenues generated by the
company's products and certain costs of producing those revenues, such as
costs of product sales, research and development and selling, general and
administrative expenses. We use the following measures, which are not
calculated in accordance with Generally Accepted Accounting Principles
("GAAP"): non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating
expenses, non-GAAP other income and expense, non-GAAP tax rate, non-GAAP net
income, non-GAAP net income per diluted share and non-GAAP shares used to
compute diluted net income per share. These are non-GAAP financial measures
under Section 101 of Regulation G under the Securities Exchange Act of 1934,
as amended. These non-GAAP financial measures are calculated by excluding
certain GAAP financial items that we believe have less significance to the
day-to-day operation of our business. The company has outlined below the type
and scope of these exclusions and the limitations on the use of the non-GAAP
financial measures as a result of these exclusions.

Management uses these non-GAAP financial measures for financial and
operational decision making, including in the determination of employee annual
cash incentive compensation, as a means to evaluate period-to-period
comparisons, as well as comparisons to our competitors' operating results.
Management also uses this information internally for forecasting and
budgeting, as it believes that the measures are indicative of Thoratec core
operating results. Management also believes that non-GAAP financial measures
provide useful supplemental information to management and investors regarding
the performance of the company's business operations, provide a greater
transparency with respect to key metrics used by management in its decision
making, facilitate comparisons of results for current periods and guidance for
future periods with our historical operating results, and assist in analyzing
future trends.

Non-GAAP net income consists of GAAP net income, excluding, as applicable, the
tax effected impact of share-based compensation expense, amortization of
purchased intangibles, expenses associated with the accounting for convertible
debt instruments that may be settled in cash upon conversion, including
partial settlements in accordance with Financial Accounting Standards Board
("FASB") issued Accounting Standards Codification ("ASC") 470-20, Debt,
Levitronix Medical transaction costs, and Levitronix fair market value (FMV)
inventory adjustments. 

Non-GAAP net income per diluted share is defined as non-GAAP net income
divided by the weighted average number of shares on a fully-diluted basis.

Non-GAAP shares used to compute diluted net income per share consists of GAAP
shares used to compute diluted net income per share adjusted for any
inclusions made in conjunction with dilutive impact of Thoratec's convertible
debt instruments and any exclusions made in conjunction with the application
of the two-class method for calculating net income per share.

Non-GAAP gross profit and gross margin consist of GAAP gross profit and gross
margin excluding share-based compensation expense, amortization of
intangibles, and Levitronix Medical FMV inventory adjustments related to the
acquisition.

Non-GAAP operating expenses consist of GAAP operating expenses excluding
share-based compensation expense, amortization of purchased intangibles, and
Levitronix Medical transaction costs.

Non-GAAP other income and expense consists of GAAP other income and expenses
excluding expenses related to the accounting for convertible debt instruments
that may be settled in cash upon conversion, including partial settlements, in
accordance with ASC 470-20, Debt.

Non-GAAP tax expense consists of the GAAP tax expense adjusted for the tax
effect of the adjustments from GAAP net income to non-GAAP net income.

Management believes that it is useful in measuring Thoratec's operations to
exclude amortization of intangibles. These costs are primarily fixed at the
time of an acquisition and, unlike other fixed costs that result from ordinary
operations, are the result of infrequent and irregular events.

Because of varying valuation methodologies, subjective assumptions and the
variety of award types that companies can use, Thoratec management believes
that providing non-GAAP financial measures that exclude share-based
compensation allows investors to compare Thoratec's recurring core business
operating results to those of other companies and over multiple periods. The
exclusion also enhances investors' ability to review Thoratec's business from
the same perspective as Thoratec management, which believes that share-based
compensation expense is not directly attributable to the underlying
performance of the company's business operations.

Due to the subjective assumptions used to develop non-cash interest expense
related to the accounting for convertible debt instruments that may be settled
in cash upon conversion, including partial settlements, in accordance with ASC
470-20, Debt, Thoratec management believes that providing non-GAAP financial
measures that exclude such expense allows investors to compare Thoratec's
recurring core business operating results to those of other companies and over
multiple periods. The exclusion also enhances investors' ability to review
Thoratec's business from the same perspective as Thoratec management.

To enable investors to compare Thoratec's recurring core business operating
results to those of other companies and over multiple periods, Thoratec has
excluded Levitronix Medical transaction costs and FMV inventory adjustments as
they are infrequent in nature.

There are a number of limitations related to the use of non-GAAP financial
measures. First, non-GAAP financial measures exclude some costs, namely
share-based compensation, that are recurring expenses. Second, share-based
compensation is part of an employee's compensation package and as such may be
useful for investors to consider. Third, the components of costs that we
exclude in our non-GAAP financial measures calculations may differ from
components that our peer companies exclude when they report their results from
operations.

Non-GAAP financial measures should not be considered as a substitute for
measures of financial performance in accordance with GAAP. However, these
measures may provide additional insight into Thoratec's financial results.
Investors and potential investors are strongly encouraged to review the
reconciliation of non-GAAP financial measures contained within this press
release with their most directly comparable GAAP financial results and not to
rely on any single financial measure to evaluate our business.

The reconciliations of the forward looking non-GAAP financial measures to the
most directly comparable GAAP financial measures in the tables below include
all information reasonably available to Thoratec at the date of this press
release. These tables include adjustments that we can reasonably predict.
Events that could cause the reconciliation to change include acquisitions and
divestitures of business, goodwill and other asset impairments and sales of
marketable equity securities.

The following table includes the GAAP income statement for continuing
operations for the three and nine month periods ending 2012 and 2011:

THORATEC CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except for per share data)
                        Three Months Ended        Nine Months Ended
                        September 29,  October 1,   September 29,  October 1,
                        2012           2011         2012           2011
Product sales           $           $ 102,584   $           $ 313,335
                        117,768                    363,196
Cost of product sales   36,162         32,937       111,071        99,051
Gross profit            81,606         69,647       252,125        214,284
Operating expenses:
Selling, general and    28,478         25,632       91,692         77,375
administrative
Research and            20,382         16,273       59,886         47,826
development
Total operating         48,860         41,905       151,578        125,201
expenses
Income from operations  32,746         27,742       100,547        89,083
Other income and
(expense):
Interest expense        -              (3)          (3)            (4,650)
Interest income and     579            283          1,401          1,526
other
Income before income    33,325         28,022       101,945        85,959
taxes
Income tax expense     (9,070)        (9,033)      (31,396)       (28,729)
Net income from         $          $  18,989  $          $  57,230
continuing operations   24,255                     70,549
Net (loss) from
discontinued            $        $           $        $ 
operations (net of         -       (1,031)        -       (1,031)
tax)
Net Income              $          $  17,958  $          $  56,199
                        24,255                     70,549
Net income (loss) per
share- Basic:
Continuing operations   $        $         $        $   
                        0.41          0.32        1.20          0.97
Discontinued            -              (0.02)       -              (0.02)
operations
Net Income              $        $         $        $   
                        0.41          0.30        1.20          0.95
Net income (loss) per
share- Diluted:
Continuing operations   $        $         $        $   
                        0.41          0.31        1.18          0.95
Discontinued            -              (0.02)       -              (0.02)
operations
Net Income              $        $         $        $   
                        0.41          0.29        1.18          0.93
Shares used to compute
net (loss) income per
share:
Basic                   58,762         59,763       58,645         58,630
Diluted                 59,669         60,666       59,609         63,306

The following table presents our quarterly revenues from continuing operations
by source for the first, second and third quarter of fiscal 2012 and for the
full year of fiscal 2011:

THORATEC CORPORATION
Quarterly Revenue Analysis
(Unaudited)
(in millions)
                   Three Months Ended
                   Sept 29,  Jun 30,  Mar 31,  Dec 31,  Oct 1,  Jul 2,   Apr
                   2012      2012     2012     2011     2011    2011     2,
                                                                         2011
Revenue by Product
Line
                   $      $     $     $     $     $     $  
HeartMate                                            97.6    
                   105.9    106.2    111.7   93.8    87.6             87.3
PVAD & IVAD        3.8       3.8      5.8      6.1      7.2     7.6      7.3
CentriMag (1)      7.5       8.0      8.7      8.8      7.2     5.3      4.4
Other              0.6       0.6      0.6      0.7      0.6     0.7      0.5
                   $      $     $     $     $     $     $  
Total                                                 111.2     
                   117.8    118.6    126.8   109.4   102.6            99.5
Revenue by
Category
                   $      $     $     $     $     $     $  
Pump                                              77.8    
                   85.0     85.7     92.6    77.4    72.2             70.8
Non-Pump           32.2      32.3     33.6     31.3     29.8    32.7     28.2
Other              0.6       0.6      0.6      0.7      0.6     0.7      0.5
                   $      $     $     $     $     $     $  
Total                                                 111.2     
                   117.8    118.6    126.8   109.4   102.6            99.5
Revenue by
Geography
                   $      $     $     $     $     $     $  
United States                                      93.0    
                   97.5     97.1     103.9   88.2    83.9             82.5
International      20.3      21.5     22.9     21.2     18.7    18.2     17.0
                   $      $     $     $     $     $     $  
Total                                                 111.2     
                   117.8    118.6    126.8   109.4   102.6            99.5
(1) CentriMag includes
PediMag/PediVAS® sales

The following table presents our quarterly pump units from continuing
operations by geography for the first, second and third quarter of fiscal 2012
and for the full year of fiscal 2011:

THORATEC CORPORATION
Quarterly Pump Units
(Unaudited)
                   Three months ended
                   Sept    Jun 30,   Mar 31,   Dec 31,  Oct 1,  Jul 2,  Apr 2,
Units by Geography 29,     2012      2012      2011     2011    2011    2011
                   2012
United States      781     773       838       704      665     753     677
International      208     212       219       213      188     193     182
Total (1)          989     985       1,057     917      853     946     859
(1) Excludes CentriMag and PediMag/PediVAS
units

The following table reconciles the specific items excluded from GAAP net
income from continuing operations in the calculation of non-GAAP net income
from continuing operations and diluted net income per share from continuing
operations for the periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Net Income
(Unaudited)
(in thousands, except for per share data)
                               Three Months Ended      Nine Months Ended
Net income reconciliation      September      October    September    October
                               29, 2012       1, 2011    29, 2012     1, 2011
Net income from continuing     $         $         $         $ 
operations on a GAAP basis     24,255         18,989    70,549      57,230
Share-based compensation
expense:
- Cost of product sales        548            378        1,525        1,081
- Selling, general and         3,442          2,539      9,829        7,578
administrative
- Research and development     1,576          1,011      4,678        3,073
Amortization of purchased
intangibles
- Cost of product sales        2,066          2,039      6,209        6,008
- Selling, general and         587            570        1,789        1,100
administrative
- Research and development     83             -          246          -
Impact of ASC 470-20 (Debt)    -              -          -            3,127
Levitronix Medical FMV         (102)          1,386      530          1,386
inventory adjustments
Levitronix Medical                            1,462                   2,859
transaction costs
Income tax effect of           (3,225)        (3,264)    (8,737)      (9,107)
non-GAAP adjustments
Net income from continuing     $         $         $         $ 
operations on a non-GAAP       29,230         25,110    86,618      74,335
basis
                               Three Months Ended      Nine Months Ended
Diluted net income per share   September      October    September    October
reconciliation                 29, 2012       1, 2011    29, 2012     1, 2011
Diluted net income from        $         $       $       $   
continuing operations per        0.41       0.31      1.18        0.95
share on a GAAP basis
Share-based compensation
expense:
- Cost of product sales        0.01           0.01       0.03         0.02
- Selling, general and         0.06           0.04       0.16         0.12
administrative
- Research and development     0.03           0.02       0.08         0.05
Amortization of purchased
intangibles
- Cost of product sales        0.03           0.03       0.10         0.09
- Selling, general and         0.01           0.01       0.03         0.02
administrative
- Research and development     0.00           -          0.00         -
Levitronix Medical FMV         (0.01)         0.02       0.01         0.02
inventory adjustments
Levitronix Medical             -              0.02       -            0.05
transaction costs
Income tax effect of           (0.05)         (0.05)     (0.14)       (0.14)
non-GAAP adjustments
Diluted net income from        $         $       $       $   
continuing operations per        0.49       0.41      1.45        1.18
share on a non-GAAP basis
                               Three Months Ended      Nine Months Ended
                               September      October    September    October
                               29, 2012       1, 2011    29, 2012     1, 2011
Shares used to compute
diluted net income per share
reconciliation
Shares used in calculation
of diluted net income per      59,669         60,666     59,609       63,306
share -- GAAP
Weighted average unvested      -              75         17           111
restricted stock awards (1)
Shares used in calculation
of diluted net income per      59,669         60,741     59,626       63,417
share -- non-GAAP
        The company adopted the two-class method in calculating net income per
        share on a GAAP basis, which excludes the weighted average unvested
(1)     restricted stock awards outstanding of 0 and 75,000 for the three
        months ended September 29, 2012 and October 1, 2011, respectively and
        17,000 and 111,000 for the nine months ended September 29, 2012 and
        October 1, 2011, respectively.

The following table reconciles the specific items excluded from GAAP gross
profit and gross margin from continuing operations in the calculation of
non-GAAP gross profit and gross margin from continuing operations for the
periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Gross Profit
(Unaudited)
(in thousands)
                  Three Months Ended           Nine Months Ended
                  September       October        September       October
                  29, 2012        1, 2011        29, 2012        1, 2011
Gross profit on a $     69.3% $      67.9%  $      69.4% $     68.4%
GAAP basis        81,606         69,647        252,125         214,284
Share-based
compensation      548             378            1,525           1,081
expense
Amortization of   2,066           2,039          6,209           6,008
intangibles
Levitronix
Medical FMV       (102)           1,386          530             1,386
inventory
adjustments
Gross profit on a $     71.4% $      71.6%  $      71.7% $     71.1%
non-GAAP basis    84,118         73,450        260,389         222,759

The following table reconciles the specific items excluded from GAAP operating
expenses from continuing operations in the calculation of non-GAAP operating
expenses from continuing operations for the periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Operating Expenses
(Unaudited)
(in thousands)
                          Three Months Ended       Nine Months Ended
                          September 29,  October 1,  September 29,  October 1,
                          2012           2011        2012           2011
Operating expenses on a  $          $  41,905  $            $ 125,201
GAAP basis               48,860                     151,578
Share-based compensation
expense:
- Selling, general and    (3,442)        (2,539)     (9,829)        (7,578)
administrative
- Research and            (1,576)        (1,011)     (4,678)        (3,073)
development
Amortization of
purchased intangibles
- Selling, general and    (587)          (570)       (1,789)        (1,100)
administrative
- Research and            (83)           -           (246)          -
development
Levitronix Medical        -              (1,462)     -              (2,859)
transaction costs
Operating expenses on a  $          $  36,323  $            $ 110,591
non-GAAP basis           43,172                     135,036

The following table reconciles the specific items excluded from GAAP other
income and expense from continuing operations in the calculation of non-GAAP
other income and expense from continuing operations for the periods shown
below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Other Income and Expense
(Unaudited)
(in thousands)
                        Three Months Ended        Nine Months Ended
                        September 29,  October 1,   September 29,  October 1,
                        2012           2011         2012           2011
Other income           $                     $     
(expense) on a GAAP     579           $    280  1,398          $  (3,124)
basis
Impact of ASC 470-20    -              -            -              3,127
(Debt)
Other income           $                     $         $     
(expense) on a          579           $    280  1,398          3
non-GAAP basis

The following table reconciles the GAAP tax expense adjusted for the tax
effect of the adjustments from GAAP net income from continuing operations to
non-GAAP net income from continuing operations:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Tax Expense
(Unaudited)
(in thousands)
                  Three Months Ended           Nine Months Ended
                  September       October        September       October
                  29, 2012        1, 2011        29, 2012        1, 2011
Tax expense on a  $     27.2% $    32.2%  $     30.8% $    33.4%
GAAP basis         9,070         9,033        31,396          28,729
Share-based
compensation      1,694           1,154          6,170           4,389
expense
Amortization of
purchased         1,007           1,044          3,031           2,843
intangibles
Impact of
adoption of ASC   -               -              -               1,251
470-20 (Debt)
Excess
compensation      565             (72)           (675)           (1,074)
limitations and
other
Levitronix
Medical FMV       (41)            554            211             554
inventory
adjustments
Levitronix
Medical           -               585            -               1,144
transaction costs
Tax expense on a  $     29.6% $    32.9%  $     31.7% $    33.7%
non-GAAP basis    12,295         12,298         40,133          37,836

The following table reconciles the guidance on a GAAP basis and non-GAAP basis
from continuing operations for the periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Forward-Looking Guidance
(Unaudited)
(in thousands, except for per share data)
Gross margin                                  For the Fiscal Year Ended 2012
Gross margin on a GAAP basis                                 69.00%
Amortization of purchased intangibles                        1.80%
Levitronix Medical FMV inventory adjustments                 0.30%
Share-based compensation expense                             0.40%
Gross margin on a non-GAAP basis                             71.50%
Net income per diluted share reconciliation   For the Fiscal Year Ended 2012
                                              From                   To
Net income from continuing operations per     $    1.40          $  1.44
diluted share on a GAAP basis
Share-based compensation expense              0.26                   0.26
Amortization of purchased intangibles         0.12                   0.12
Levitronix Medical FMV inventory adjustments  0.01                   0.01
Net income from continuing operations per     $    1.79          $  1.83
diluted share on a non-GAAP basis

About Thoratec

Thoratec is the world leader in mechanical circulatory support with the
broadest product portfolio to treat the full range of clinical needs for
patients suffering from advanced heart failure. The company's products include
the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted
in patients suffering from heart failure. Thoratec also manufactures and
markets the CentriMag and PediMag / PediVAS product lines. Thoratec is
headquartered in Pleasanton, California. For more information, visit
www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered
trademarks of Thoratec Corporation and HeartMate PHP and IVAD are trademarks
of Thoratec Corporation. CentriMag and PediMag are registered trademarks of
Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland
GmbH.

Many of the preceding paragraphs, particularly but not exclusively those
addressing guidance for fiscal 2012 financial results or future performance
contain forward-looking statements within the meaning of Sections 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements can be identified by the words, "believes," "views,"
"expects," "plans," "projects," "hopes," "could," "will," and other similar
words. Actual results, events or performance could differ materially from
these forward-looking statements based on a variety of factors, many of which
are beyond Thoratec's control. Therefore, readers are cautioned not to put
undue reliance on these statements. Investors are cautioned that all such
statements involve risks and uncertainties, including risks related to
regulatory approvals, the development of new products, including development
and clinical trial timing, and new markets including Destination Therapy, the
growth of existing markets for our products, customer and physician acceptance
of Thoratec products, changes in the mix of existing markets for our products
and related gross margin for such product sales, the ability to improve
financial performance, the effects of FDA regulatory requirements, our ability
to address issues raised by FDA inspections adequately and on a timely basis
without a resulting recall of products or interruption of manufacturing or
shipment of products, the effects of healthcare reimbursement and coverage
policies, the effects of seasonality on Thoratec product sales, the effects of
competition and the effects of any merger, acquisition and divestiture related
activities. Forward-looking statements contained in this press release should
be considered in light these factors and those factors discussed from time to
time in Thoratec's public reports filed with the Securities and Exchange
Commission, such as those discussed under the heading, "Risk Factors," in
Thoratec's most recent annual report on Form 10-K, quarterly reports on Form
10-Q, current reports on Form 8-K and other SEC filings. These forward-looking
statements speak only as of the date hereof. Thoratec undertakes no obligation
to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances after the date
hereof, or to reflect the occurrence of unanticipated events.

SOURCE Thoratec Corporation

Website: http://www.thoratec.com
Contact: Taylor Harris, Vice President and Chief Financial Officer, Thoratec
Corporation, (925) 738-0047
 
Press spacebar to pause and continue. Press esc to stop.